The muscarinic M3 receptor (M3R) is a Gq-coupled receptor and is known to interact with many intracellular regulatory proteins. One of these molecules is Gβ5-RGS7, the permanently associated heterodimer of G protein β-subunit Gβ5 and RGS7, a regulator of G protein signaling. Gβ5-RGS7 can attenuate M3R-stimulated release of Ca(2+) from intracellular stores or enhance the influx of Ca(2+) across the plasma membrane. Here we show that deletion of amino acids 304-345 from the central portion of the i3 loop renders M3R insensitive to regulation by Gβ5-RGS7. In addition to the i3 loop, interaction of M3R with Gβ5-RGS7 requires helix 8. According to circular dichroism spectroscopy, the peptide corresponding to amino acids 548-567 in the C-terminus of M3R assumes an α-helical conformation. Substitution of Thr553 and Leu558 with Pro residues disrupts this α-helix and abolished binding to Gβ5-RGS7. Introduction of the double Pro substitution into full-length M3R (M3R(TP/LP)) prevents trafficking of the receptor to the cell surface. Using atropine or other antagonists as pharmacologic chaperones, we were able to increase the level of surface expression of the TP/LP mutant to levels comparable to that of wild-type M3R. However, M3R-stimulated calcium signaling is still severely compromised. These results show that the interaction of M3R with Gβ5-RGS7 requires helix 8 and the central portion of the i3 loop.
The muscarinic M3 receptor (M3R) is a Gq-coupled receptor and is known to interact with many intracellular regulatory proteins. One of these molecules is Gβ5-RGS7, the permanently associated heterodimer of G protein β-subunit Gβ5 and RGS7, a regulator of G protein signaling. Gβ5-RGS7 can attenuate M3R-stimulated release of Ca(2+) from intracellular stores or enhance the influx of Ca(2+) across the plasma membrane. Here we show that deletion of amino acids 304-345 from the central portion of the i3 loop renders M3R insensitive to regulation by Gβ5-RGS7. In addition to the i3 loop, interaction of M3R with Gβ5-RGS7 requires helix 8. According to circular dichroism spectroscopy, the peptide corresponding to amino acids 548-567 in the C-terminus of M3R assumes an α-helical conformation. Substitution of Thr553 and Leu558 with Pro residues disrupts this α-helix and abolished binding to Gβ5-RGS7. Introduction of the double Pro substitution into full-length M3R (M3R(TP/LP)) prevents trafficking of the receptor to the cell surface. Using atropine or other antagonists as pharmacologic chaperones, we were able to increase the level of surface expression of the TP/LP mutant to levels comparable to that of wild-type M3R. However, M3R-stimulated calcium signaling is still severely compromised. These results show that the interaction of M3R with Gβ5-RGS7 requires helix 8 and the central portion of the i3 loop.
The G protein-coupled
receptors
(GPCRs) respond to a large variety of extracellular signals and make
up the largest receptor gene family. The canonical mechanism of signal
transduction initiated by GPCRs involves activation of heterotrimeric
G proteins, passing the signal onto effector enzymes and ion channels,
which in turn regulate the intracellular concentration of second messengers,
i.e., cAMP and Ca2+.[1] In addition
to G proteins, GPCRs interact with a plethora of molecules, including
arrestins, protein kinases, adaptor proteins, PDZ domain-containing
proteins, and regulators of G protein signaling (RGS).[2] While interactions with G proteins and arrestins are characteristic
of essentially all GPCRs, these other accessory proteins interact
with only some GPCRs.Among the known binding partners of GPCRs
are regulators of G protein
signaling (RGS) proteins, which are GTPase-activating proteins (GAPs)
for G proteins, classically serving as negative regulators of GPCR
signaling.[3,4] Approximately 30 mammalianRGS proteins
have been identified and are divided among eight subfamilies on the
basis of structural similarities.[5] The
R7 subfamily of RGS proteins, RGS6, -7, -9, and -11, uniquely form
an obligate heterodimer with the G protein β-subunit β5
(Gβ5). All R7 RGS proteins contain an N-terminal DEP (Disheveled,
Egl10, and Plekstrin homology) domain, followed by DHEX (DEP Helical
EXtension), GGL (G-Gamma-Like), and C-terminal RGS domains. Association
of Gβ5 with the R7-RGS GGL domain stabilizes the heterodimer
protecting each protein from degradation.[6,7] The
RGS domain harbors its GAP activity, and the DEP domain facilitates
membrane targeting and is involved in protein–protein interactions
and possibly selectivity.[8−10]Gβ5-RGS7 and Gβ5-RGS9
complexes can interact with some
GPCRs, specifically the dopamine D2 receptor (D2R),[11] an orphan receptor GPR158,[12] and the muscarinic M3 receptor (M3R).[6,13−16] There are five muscarinic receptors: in physiological settings,
the paradigm is one in which M1, M3, and M5 are coupled to Gαq
whereas M2 and M4 are coupled to Gαi.[17,18] The Gβ5-RGS7 complex selectively attenuates M3R-stimulated
Ca2+ signaling and has no effect on the other muscarinic
receptors.[15] Accordingly, the unique third
intracellular (i3) loop and cytoplasmic tail (c-tail) of M3R selectively
bind to the Gβ5-RGS7 complex.[15] The
i3 loop of M3R is an important region involved in receptor dimerization,
G protein recognition, and coupling and interaction with several other
proteins.[19−23]The proximal portion of the carboxyl terminus of M3R contains
an
α-helix, which is commonly termed helix 8.[24] To date, structural and biophysical evidence suggests that
helix 8 is a common feature that plays an important role in GPCR localization
and signal transduction.[25−30] The conformational dynamics of helix 8 has been shown to be dependent
on the ligand and binding partner.[29,31] In this study,
we used protein interaction analysis, spectroscopy, and signaling
assays to delineate the structural basis of M3R signal transduction
regulation by the Gβ5-RGS7 complex.
Experimental Procedures
Reagents
and Antibodies
Fluo-8 and fura2-AM were from
Abcam and Life Techologies, respectively. All other reagents were
purchased from Sigma-Aldrich, unless otherwise stated. Rabbit antibody
for Gβ5 (1:1000 WB and 1:300 IF) was described previously (REF).
Mouse anti-GFP antibody JL-8 was from Clontech (1:3000 WB and 1:1000
IF), and anti-rabbit (1:5000) and anti-mouse (1:3000) secondary antibodies
conjugated to horseradish peroxidase were from Jackson Laboratories.
Anti-rabbitfluorescein-labeled antibodies (1:400) were from Amersham
Biosciences, and the anti-mouseCy3-labeled antibody (1:400) was from
Sigma-Aldrich.
Cloning and Purification of GST-M3R Constructs
All
constructs were cloned into the pGEX-2T vector (GE Healthcare) at BamHI and EcoRI sites. The GST fusions
(GST-M3CT-K → A, GST-M3CT-CT, GST-M3CT-NT, and GST-M3CT-TP/LP)
were made by polymerase chain reaction (PCR) mutagenesis and verified
by sequencing. GST fusion proteins were expressed in Escherichia
coli and purified on glutathione beads using a standard protocol
described previously.[16] Briefly, 1 L bacterial
cultures were grown to an OD600 of 1.0 at 37 °C. Protein
expression was induced with the addition of 0.4 mM IPTG for 1.5–2
h at 30 °C. Cells were pelleted and stored at −80 °C
until they were used further. Pellets were resuspended in BugBuster
Master Mix lysis buffer (Novagen) supplemented with protease inhibitors
(Complete, Roche). Protein solubilization was achieved by adding the
ionic detergent N-lauroylsarcosine to a concentration
of 1.5% for 10 min at room temperature. N-Lauroylsarcosine
was sequestered by Triton X-100 (final concentration of 2%), and the
lysate was centrifuged at 19000 rpm and 4 °C for 30 min. Glutathione-Sepharose
4B beads (GE) were incubated with lysate for 2 h and washed with PBS.
Bound GST fusion proteins were eluted with 20 mM glutathione, desalted
on Sephadex G-25 pre-equilibrated with buffer containing 100 mM Tris-HCl
(pH 8.0), 150 mM NaCl, and 15% glycerol, and stored frozen in aliquots
at −80 °C. The protein concentration was determined using
the Bio-Rad protein assay kit according to the manufacturer’s
recommendations with bovine serum albumin as a standard. The concentration
of the frozen GST-M3R protein stock was 2.5 mg/mL (∼65 μM).
The purity of GST was >90% as determined by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis.
Constructs for Expression in Mammalian Cells
Constructs
encoding Gβ5 and RGS7 genes were previously described.[16] The constructs encoding the human muscarinic
M3 receptor gene (M3R) and an N-terminal HA-tagged M3R (HA-M3R) in
a pcDNA3.1 vector were purchased from cDNA.org. These constructs were
used for subsequent cloning of M3R and HA-M3R mutants [M3RΔ304–390, M3RΔ304–325, M3RΔ324–345, M3RΔ370–390, and M3RTP/LP (see
the text)] utilizing PCR mutagenesis techniques.
Cell Culture
and Transfection
Chinese hamster ovary
(CHO-K1) cells were cultured in F-12K medium with 10% fetal bovine
serum and penicillin/streptomycin. Twenty-four hours prior to transfection,
cells were seeded on 12 mm glass coverslips, 10 cm plates, or 6-well
plates, as required by the experiment, to achieve 50–75% confluency
at the time of transfection. Lipofectamine2000 transfection reagent
(Life Technologies) was used according to the manufacturer’s
guidelines at a 2:1 reagent:DNA ratio. The total amount of DNA for
12 mm coverslip transfections was 0.5 μg and was scaled up according
to the relative surface for transfection in larger vessels. The ratio
of Gβ5 to RGS7 was always 1:3, and for cotransfection with M3R
and Gβ5-RGS7, the DNA ratio was 1:1:3. Empty pcDNA3.1 or LacZ plasmid DNA was used to ensure constant DNA loading
in cotransfections. Forty-eight hours after transfection, cells were
used for Ca2+ imaging or immunofluorescence studies. For
GST pull-down assays, cells were washed in ice-cold PBS and scraped
in a hypotonic lysis buffer containing 20 mM Tris-HCl, 5 mM NaCl2, 1 mM MgCl2, 2 mM CaCl2, 1 mM DTT,
1 mM EDTA, 1 mM EGTA, and protease inhibitors, followed by two freeze–thaw
cycles at −80 °C and centrifugation for 45 min at 4 °C
and 20000g. The resulting supernatant was collected
and used in the GST pull-down assay. Fresh lysate was prepared for
each experiment.
GST Pull-Down Assay
As previously
described,[16] Glutathione-Sepharose 4B beads
were prewashed
with PBS and 0.1% CHAPS, incubated at 4 °C with purified recombinant
GST or the GST fusion proteins for 1 h, and washed three times with
PBS and 0.1% CHAPS to remove excess protein. The slurry was incubated
for 1–2 h at 4 °C on a rotary shaker with the various
lysates as determined by the experiment. At the end of the incubation,
the beads settled because of gravity, and the supernatant was collected
as the unbound fraction. The resin was extensively washed and subsequently
eluted with the addition of sodium dodecyl sulfate (SDS)-containing
sample loading buffer. In a typical assay, the packed volume of the
GST resin was 30 μL, the amount of loaded GST fusion protein
was 10 μg, and the volume of the protein lysate was 300 μL.
The total protein concentration in transfected cell lysates was 2.5–5.0
mg/mL. The beads were washed three times with 600 μL of PBS
and 0.1% CHAPS buffer and eluted with 30 μL of 2× SDS sample
loading buffer. The unbound and eluted fractions were resolved by
gel electrophoresis and analyzed by Western blotting with chemiluminescent
detection. Films were scanned, and densitometric measurements of the
bands were calculated using ImageJ.
Immunofluorescence
Transfected CHO-K1 cells grown on
glass coverslips were fixed with 4% paraformaldehyde and incubated
for 30 min a blocking buffer containing 1% BSA in PBS with or without
0.1% Triton X-100, as determined by the experiment. Antibodies were
diluted in blocking buffer and incubated with fixed cells for 30 min
each with three washes with PBS between and after antibody incubations.
Coverslips were affixed to glass slides using ProLong Gold Antifade
with DAPI (Life Technologies). After drying overnight, slides were
ready for imaging.
Flow Cytometry
For the analysis
of M3R surface expression,
transfected CHO-K1 cells were rinsed with PBS and detached by incubation
with 1 mM EGTA and 5 mM EDTA in PBS. After cells were washed once
in 1 mL of staining buffer [PBS (pH 7.2), 0.5% BSA, and 2 mM EDTA],
they were resuspended in 100 μL of staining buffer with 10 μL
of mouse anti-HA phycoerythrin-conjugated antibody (130-092-257, Miltenyi
Biotec GmbH) and incubated for 10 min in the dark (8 °C). Cells
were washed in 2 mL of staining buffer by centrifugation at 300g for 5 min and resuspended in 1 mL of 0.5% formaldehyde
in PBS. Flow cytometry was performed using a Becton Dickinson LSR
II instrument with 10000 events acquired per sample.
Ca2+ Imaging Microscopy
As previously described,[13] transiently transfected CHO-K1 cells grown on
12 mm glass coverslips were washed with culture medium and then incubated
at 37 °C in culture medium containing 2 μM fura2-AM for
25 min. After fura2-AM loading, the cells were kept at ambient temperature
for no longer than 1.5 h before being imaged. Coverslips were secured
in a flow chamber and mounted on the stage of a Nikon TE2000 inverted
fluorescence microscope. The cells were continuously superfused by
gravity flow with HBSS either with or without CaCl2 and
MgCl2 (Life Technologies). As required by the experiment,
the flow was switched to agonist-containing HBSS for a specified time
and then changed back to agonist-free buffer. Images were collected
in real time every 3 s using a 20× UV objective lens and recorded
using Metafluor software. The excitation wavelengths were 340 nm (Ca2+-bound) and 380 nm (Ca2+-free), and the emission
was set to 510 nm. The 340 nm:380 nm ratio is representative of the
intracellular free Ca2+ concentration. The entire field
of view was selected as a region of interest (ROI). A typical ROI
contained 50–70 cells, of which 30–50 were YFP-positive.
The number of cells responding to muscarinic agents varied with agonist
concentration but was typically 25–35 in a particular ROI.
Traces shown here are averages of two to four independent experiments
with three replicate coverslips per experiment.
FLIPR Ca2+ Imaging
Cells were transfected
in 10 cm dishes. At 24 h post-transfection, cells were seeded in a
black-walled 384-well plate at a density of 10000 cells/well. The
Fluo-8 No Wash Calcium Assay kit (Abcam, ab112129) was used according
to the manufacturer’s recommendations. With this system, there
is no washing step after incubation with the Ca2+ indicator
as there is a quenching dye that is not membrane permeant, thus reducing
the signal of the extracellular dye. Briefly, growth medium was removed,
and cells were washed with Ca2+-free HHBSS (20 mM Hepes
in Hanks balanced salt solution). A 2× solution of the Fluo-8
dye was prepared in Ca2+-free HHBSS and 1% plurionic acid.
Equal volumes of HHBSS and Fluo-8 were added to the cells and placed
in the 37 °C incubator for 30 min. The plate was then allowed
to equilibrate to atmospheric conditions for 20 min before being analyzed
with the FLIPR Tetra system. A baseline read of plate fluorescence
of 10 s was performed prior to the addition of agonist. After agonist
application, the fluorescence intensity was recorded every second
for at least 3 min.
[3H]NMS Binding Assay
The muscarinic receptor
density was determined by the ligand binding assay using the muscarinic
antagonist N-methyl scopolamine chloride ([3H]NMS, 84.1 Ci/mmol, PerkinElmer) essentially as previously described.[15] Briefly, CHO-K1 cells were transfected in 10
cm dishes with wild-type or mutant M3R. Twenty-four hours after transfection,
cells were detached and seeded in 24-well plates at a density of 100000
cells/well, at which time atropine was added where required by the
experiment. One day after, cells were washed and incubated with 1
mL of [3H]NMS in HBSS for 30 min at room temperature. The
[3H]NMS concentration was 50 nM. Following the incubation,
cells were rapidly washed twice with 1 mL of ice-cold buffer and then
lysed with 0.25 mL of 0.1 M NaOH added to the wells. This lysate was
neutralized with 0.25 mL of 0.1 M HCl; 0.5 mL of 50 mM Hepes (pH 7.2)
was added, and the mixture was transferred to the vials for liquid
scintillation counting. Triplicate wells were used for each experimental
condition. Nonspecific binding was assessed using mock-transfected
cells.
cAMP Assay
We used the LANCE Ultra cAMP competitive
immunoassay kit (PerkinElmer); 5000 cells were seeded in 10 μL
of cell buffer (HBSS, 25 mM Hepes, and 0.1% BSA) onto 384-well microtiter
plates. Then, 5 μL of test compound prepared in assay buffer
(0.1% BSA, 25 mM Hepes, and 500 μM 3-isobutyl-1-methylxanthine)
or buffer alone was added to the appropriate wells, and plates were
incubated at room temperature for 30 min. After this incubation, 5
μL of Eu-cAMP (prepared in lysis buffer according to the manufacturer’s
protocol) followed by 5 μL of ULight-labeled anti-cAMP in the
same buffer was added to each well and incubated for 1 h at room temperature.
FRET measurements were performed using the Envision microplate reader
(PerkinElmer) at the following wavelengths: 340 nm (with a 30 nm bandwidth)
excitation and 671 nm (with a 4 nm bandwidth) emission.
Peptide Synthesis
20-mer wild-type (WT) and mutant
(TP/LP) peptides corresponding to the C-terminal tail (residues 548–567)
of M3R were commercially obtained from GenScript Corp. The amino acid
sequences of these peptides were 548-NKTFRTTFKMLLLCQCDKKK-567
(WT) and 548-NKTFRPTFKMPLLCQCDKKK-567
(TP/LP). Note that residues T553 and L558 and their proline counterparts
are depicted in bold font. The peptide concentrations were measured
gravimetrically.
Circular Dichroism
Far-UV circular
dichroism (CD) measurements
were conducted on a Jasco J-815 spectropolarimeter thermostatically
controlled at 25 °C. Briefly, 20-mer WT and TP/LP peptides were
dialyzed in 10 mM sodium phosphate (pH 7.0), and experiments were
conducted on a 50 μM sample of each peptide alone in solution
or in the presence of 5 mM n-dodecylphosphocholine
(DPC) bicelles (Avanti Polar Lipids). The DPC bicelles were prepared
at a stock concentration of 10 mM in 10 mM sodium phosphate (pH 7.0)
by being stirred for 2h at 37 °C. Data were collected using a
quartz cuvette with a 2 mm path length in the 185–255 nm wavelength
range and with a slit bandwidth of 2 nm at a scan rate of 10 nm/min.
All data were normalized against reference spectra to remove the contribution
of buffer. Each data set represents an average of four scans acquired
at 0.1 nm intervals. Data were converted to mean ellipticity, [θ],
as a function of wavelength (λ) of electromagnetic radiation
using the following equation:where Δε
is the observed ellipticity
in millidegrees, c is the peptide concentration in
micromolar, and l is the cuvette path length in centimeters.
Molecular Modeling
Structural models of WT and TP/LP
peptides (residues 548–567) were built using the MODELER software
based on homology modeling.[32] In each case,
the crystal structure of the CHRM3 receptor (Protein Data Bank entry 4DAJ) harboring helix
H8 (residues 548–556) was used as a template.[24] For each peptide, a total of 100 atomic models were calculated,
and the structure with the lowest energy, as judged by the MODELER
Objective Function, was selected for further analysis. The structural
models were rendered using RIBBONS.[33]
Molecular Dynamics
Molecular dynamics (MD) simulations
were performed with GROMACS[34] using the
integrated AMBER99SB-ILDN force field.[35,36] Briefly, the
structural models of WT and TP/LP peptides (residues 548–567)
were each centered in a cubic box and explicitly hydrated with a water
layer that extended 10 Å (box size) from the protein surface
along each orthogonal direction using the extended simple point charge
(SPC/E) water model.[37,38] The ionic strength of the solution
was set to 100 mM with NaCl, and the hydrated structures were energy-minimized
with the steepest descent algorithm prior to equilibration under the NPT ensemble conditions, wherein the number of atoms (N), pressure (P), and temperature (T) within the system were kept constant. The particle mesh
Ewald (PME) method[39] was employed to compute
long-range electrostatic interactions with a spherical cutoff of 10
Å and a grid space of 1.6 Å with a fourth-order interpolation.
The linear constraint solver (LINCS) algorithm was used to restrain
bond lengths.[40] All MD simulations were
performed at 300 K under periodic boundary conditions (PBC), to mimic
the bulk solvent effect, using the standard “md” leapfrog
integrator to solve Newton’s equations of motion with a time
step of 2 fs. For the final MD production runs, data were collected
every nanosecond over a time scale of 1 μs. All MD simulations
were performed on a Linux workstation using parallel processors at
the High Performance Computing (HPC) facility within the Center for
Computational Science (CCS) of the University of Miami.
Results
Residues
304–345 of the i3 Loop of M3R Are Required for
Its Regulation by Gβ5-RGS7
To extend our earlier finding
that the M3R i3 loop is required for the interaction with Gβ5-RGS7,[15] we created and analyzed several deletion mutants
in this region (Figure 1). First, we studied
deletion of amino acids 304–390, which were previously identified
by a GST pull-down assay as the region involved in the interaction
with Gβ5-RGS7.[15] Deletion of this
region within the full-length receptor (M3RΔ304–390) was tested for sensitivity to Gβ5-RGS7 in the CCh-stimulated
Ca2+ signaling assay. Consistent with previous findings,[13,15,41] Gβ5-RGS7 reduced the Emax of the M3R-stimulated Ca2+ response
to 65% of that of M3R alone (Figure 1A), with
little effect on EC50 (Table 1).
In contrast, Gβ5-RGS7 could not attenuate CCh-stimulated Ca2+ responses from the M3RΔ304–390 mutant
(Figure 1B). Compared to that of WT M3R, the Emax from M3RΔ304–390 was reduced by ∼30%; however, the EC50 remained
unchanged. These results indicate that deletion of residues 304–390
did not alter the affinity of CCh for M3R (no change in EC50) but reduced the level of surface expression and/or coupling to
Gq (reduced Emax) and abolished attenuation
by Gβ5-RGS7. Indeed, quantification of [3H]NMS binding
on intact cells overexpressing M3RΔ304–390 showed that its level was lower than that of WT by 60% (Figure 1C). Nevertheless, the dynamic range of Ca2+ responses elicited by M3RΔ304–390 is sufficient
to detect inhibition, so our results clearly show that residues 304–390
of the i3 loop are required for the negative effect of Gβ5-RGS7.
Figure 1
M3R i3
loop deletions abolish its sensitivity to Gβ5-RGS7
regulation. CHO-K1 cells were transiently transfected with WT M3R
or the i3 loop deletion mutants (M3RΔ304–325, M3RΔ325–345, M3RΔ370–390, and M3RΔ304–390) in the presence or absence
of Gβ5-RGS7 and prepared for Ca2+ imaging using FLIPR
as described in Experimental Procedures. Concentration
dependencies of the maximal change in Fluo-8 fluorescence from cells
expressing WT M3R (A), M3RΔ304–390 (B), M3RΔ304–325 (D), M3RΔ325–345 (E), and M3RΔ370–390 (F) in the absence
(black) and presence (blue) of Gβ5-RGS7 stimulated by CCh. Each
data point is the mean ± the standard error of the mean of four
replicate wells from two independent experiments. Curves were fit
using the GraphPad Prism 5 sigmoidal dose–response equation
with a variable slope and normalized to the maximal response from
cells expressing WT M3R in the absence of Gβ5-RGS7. (C) [3H]NMS binding to WT M3R and M3RΔ304–390 performed on live cells as described in Experimental
Procedures. Bar graphs show means ± SD (n = 2).
Table 1
Effects of i3 Loop
Deletions on the
Sensitivity of M3R to Gβ5-RGS7a
M3R
M3R with Gβ5-RGS7
nb
Emaxc,d
–log
EC50d,e
nb
Emaxc,d
–log
EC50d,e
WT
80
100 ± 3.94
6.35 ± 0.13
86
64 ± 3.15
6.00 ± 0.16
M3RΔ304–325
60
101 ± 3.66
6.57 ± 0.14
67
82 ± 3.11
6.56 ± 0.13
M3RΔ325–345
63
70 ± 2.78
6.82 ± 0.13
67
73 ± 2.37
6.24 ± 0.11
M3RΔ370–390
64
106 ± 2.62
6.95 ± 0.08
67
56 ± 1.60
6.66 ± 0.10
M3RΔ304–390
36
61 ± 4.05
5.61 ± 0.23
36
68 ± 10.33
4.90 ± 0.43
CCh-induced Ca2+ signaling
was measured by FLIPR in cells transfected with different M3R i3 loop
deletion mutants as described in the legend of Figure 1 and Experimental Procedures.
n is the number
of points analyzed (two independent experiments).
Emax is the maximal
change in well fluorescence expressed as a percentage
of that of WT M3R (=100%).
Mean ± the standard error of
the mean.
–Log EC50 (in
molar) is the negative logarithm of the agonist concentration that
produces the half-maximal effect.
M3R i3
loop deletions abolish its sensitivity to Gβ5-RGS7
regulation. CHO-K1 cells were transiently transfected with WT M3R
or the i3 loop deletion mutants (M3RΔ304–325, M3RΔ325–345, M3RΔ370–390, and M3RΔ304–390) in the presence or absence
of Gβ5-RGS7 and prepared for Ca2+ imaging using FLIPR
as described in Experimental Procedures. Concentration
dependencies of the maximal change in Fluo-8 fluorescence from cells
expressing WT M3R (A), M3RΔ304–390 (B), M3RΔ304–325 (D), M3RΔ325–345 (E), and M3RΔ370–390 (F) in the absence
(black) and presence (blue) of Gβ5-RGS7 stimulated by CCh. Each
data point is the mean ± the standard error of the mean of four
replicate wells from two independent experiments. Curves were fit
using the GraphPad Prism 5 sigmoidal dose–response equation
with a variable slope and normalized to the maximal response from
cells expressing WT M3R in the absence of Gβ5-RGS7. (C) [3H]NMS binding to WT M3R and M3RΔ304–390 performed on live cells as described in Experimental
Procedures. Bar graphs show means ± SD (n = 2).CCh-induced Ca2+ signaling
was measured by FLIPR in cells transfected with different M3R i3 loop
deletion mutants as described in the legend of Figure 1 and Experimental Procedures.n is the number
of points analyzed (two independent experiments).Emax is the maximal
change in well fluorescence expressed as a percentage
of that of WT M3R (=100%).Mean ± the standard error of
the mean.–Log EC50 (in
molar) is the negative logarithm of the agonist concentration that
produces the half-maximal effect.Recently, we found that the Gβ5-RGS7 complex
has a dual effect
on M3R-stimulated Ca2+ signaling: while it inhibits the
release of Ca2+ from intracellular stores, it can also
augment the influx of Ca2+ across the plasma membrane.[13] Here, we found that both Ca2+ release
and influx components were insensitive to Gβ5-RGS7 regulation
in the M3RΔ304–390 mutant (data not shown),
indicating that the region of residues 304–390 of M3R is required
for Gβ5-RGS7-mediated modulation of both Ca2+ entry
pathways.Analysis of three shorter deletions, M3RΔ304–325, M3RΔ325–345, and M3RΔ370–390, showed that removal of amino acids 304–325 or 325–345
reduced the sensitivity of M3R to the Gβ5-RGS7 complex by 18
or 27%, respectively (Figure 1D–F and
Table 1). The deletion of residues 370–390
did not reduce the sensitivity to Gβ5-RGS7 but, interestingly,
slightly enhanced attenuation of the Ca2+ response by Gβ5-RGS7.
The three smaller i3 loop deletions did not appear to affect receptor
surface expression, as the Emax was similar
to that of WT M3R (Table 1). Altogether, these
experiments have narrowed down the Gβ5-RGS7-sensitizing region
of the i3 loop of M3R to residues 304–345.
Integrity of
M3R C-Terminal Secondary Structure Is Required
for Its Interaction with Gβ5-RGS7
Previous studies
in our laboratory revealed that along with the i3 loop, regulation
by Gβ5-RGS7 involves the C-terminus of M3R, with both Gβ5
and DEP moieties binding to the recombinant M3R C-tail in
vitro.[14] To gain insights into
the structural features of the C-tail required in this interaction,
we generated four GST fusions of the C-tail and tested them in a pull-down
assay with the Gβ5-RGS7 complex (Figure 2). First, we first focused on a unique polybasic sequence, 565-KKKRRKK-570
in the middle of the C-tail, which was identified as a region necessary
for anti-apoptotic effects of the M3R[42] and a site of Gq heterotrimer preassembly.[43] In the GST-M3CT K → A construct, the first three Lys residues
were replaced with Ala (Figure 2A). We also
made two smaller fragments, GST-M3CT NT, which contained the polybasic
region, and M3CT CT, which contained the remaining C-tail (Figure 2A). As previously described,[15,16] we used lysates from CHO-K1 cells overexpressing YFP-DEP or Gβ5
complex with the RGS7R249 construct missing the DEP and
DHEX domains, to probe for interaction of DEP or Gβ5 with the
GST fusions, respectively. YFP-DEP exhibited a reduced level of binding
to all three GST fusions as compared to that of the full-length C-tail
(Figure 2B). For Gβ5 interaction, both
the NT and CT fragments exhibited reduced levels of binding (Figure 2C). Thus, the entire C-tail including the polybasic
stretch is essential for interaction with the Gβ5-RGS7 complex.
Next, we explored whether the secondary structure of the C-tail could
be important for its interaction with the Gβ5-RGS7 complex.
Figure 2
M3R helix
8 is essential for interaction with Gβ5-RGS7. Four
GST fusion proteins of the M3R CT were purified from bacteria and
tested for interaction with Gβ5-RGS7 in a pull-down assay as
described in Experimental Procedures. (A)
Amino acid sequences of M3R C-tail GST fusion proteins. The polybasic
region is underlined; the substituted Lys-to-Ala residues are shown
in bold (K → A), and the truncated fusions are designated as
NT and CT. The positions of the two residues, T553 and L558, substituted
with Pro are colored red. Purified GST fusions were immobilized on
glutathione-Sepharose 4B beads. To analyze the interaction with the
DEP domain, lysates from CHO-K1 cells expressing YFP-DEP were applied
to protein-coated beads. For Gβ5, constructs encoding Gβ5
and RGS7R249, RGS7 without the DEP domain, were cotransfected
to stabilize the Gβ5 protein. The total (T), unbound (U), and
eluted (E) material was analyzed by Western blotting using antibodies
against YFP or Gβ5 for DEP or Gβ5 detection, respectively.
Resulting blots were scanned, and the band density was quantified
using ImageJ. (B and D) Average relative density ± SD (n = 3) of DEP detected in each sample normalized to the
relative density of DEP in the eluted fraction in the pull down using
the WT C-tail. (C and E) Quantification of the average relative density
± SD (n = 3) of eluted Gβ5 in each sample
normalized to the relative density of the Gβ5 band in the WT
sample.
M3R helix
8 is essential for interaction with Gβ5-RGS7. Four
GST fusion proteins of the M3R CT were purified from bacteria and
tested for interaction with Gβ5-RGS7 in a pull-down assay as
described in Experimental Procedures. (A)
Amino acid sequences of M3R C-tail GST fusion proteins. The polybasic
region is underlined; the substituted Lys-to-Ala residues are shown
in bold (K → A), and the truncated fusions are designated as
NT and CT. The positions of the two residues, T553 and L558, substituted
with Pro are colored red. Purified GST fusions were immobilized on
glutathione-Sepharose 4B beads. To analyze the interaction with the
DEP domain, lysates from CHO-K1 cells expressing YFP-DEP were applied
to protein-coated beads. For Gβ5, constructs encoding Gβ5
and RGS7R249, RGS7 without the DEP domain, were cotransfected
to stabilize the Gβ5 protein. The total (T), unbound (U), and
eluted (E) material was analyzed by Western blotting using antibodies
against YFP or Gβ5 for DEP or Gβ5 detection, respectively.
Resulting blots were scanned, and the band density was quantified
using ImageJ. (B and D) Average relative density ± SD (n = 3) of DEP detected in each sample normalized to the
relative density of DEP in the eluted fraction in the pull down using
the WT C-tail. (C and E) Quantification of the average relative density
± SD (n = 3) of eluted Gβ5 in each sample
normalized to the relative density of the Gβ5 band in the WT
sample.Crystallographic analysis of M3R
confirms that the proximal region
of its C-tail adopts an α-helical conformation, commonly termed
helix 8.[24] To test the idea that Gβ5-RGS7
binding is dependent on the secondary structure of helix 8, we introduced
two Pro residues in place of Thr and Leu at positions 553 and 558,
respectively. We then expressed this mutant, TP/LP, as a GST fusion
protein. We found that the TP/LP mutation nearly abolished binding
of the recombinant M3R C-tail to both DEP (Figure 2D) and Gβ5 (Figure 2E).
Biophysical
Analysis of Pro-Substituted M3R Helix 8
To understand if
the TP/LP mutation indeed affects secondary structure,
we conducted far-UV CD analysis on 20-mer wild-type and mutant (TP/LP)
peptides spanning helix 8 (Figure 3B,C). Our
analysis reveals that the spectra of both WT and TP/LP peptides in
aqueous solution are characterized by a negative band centered around
200 nm (Figure 3B), characteristic of peptides
predominantly harboring random coil conformation.[44,45] However, in the membrane-like environment of DPC bicelles, the WT
peptide spectrum exhibits a positive band centered around 190 nm and two negative bands around
208 and 222 nm (Figure 3C, red line). Such
a spectral signature is a hallmark of α-helical peptides, which
strongly suggests that the WT peptide adopts an α-helical conformation
in an apolar membrane-like environment. In sharp contrast, the addition
of DPC bicelles to the TP/LP peptide does not alter its spectrum (Figure 3C, black line), implying that double Pro substitution
disrupts the α-helix.
Figure 3
In silico and biophysical analysis
of M3R helix
8. (A) Ribbon representation of the structural models of helix 8 of
WT (left) and TP/LP peptides (right). For each structural model, helix
8 is colored green, the terminal loops are colored gray, and the side
chain moieties of T553/L558 residues and their proline counterparts
are colored red. (B) Far-UV spectra of the WT peptide (40 μM)
in the absence (black) and presence (red) of 5 mM DPC. (C) Far-UV
spectra of the TP/LP peptide (40 μM) in the absence (black)
and presence (red) of 5 mM DPC. (D and E) Molecular dynamics simulations
for each peptide. Root-mean-square deviations (rmsd) of backbone atoms
(N, Cα, and C) within each simulated structure relative to the
initial modeled structure of helix 8 of M3R WT (D) and TP/LP (E) as
a function of simulation time are shown.
In silico and biophysical analysis
of M3R helix
8. (A) Ribbon representation of the structural models of helix 8 of
WT (left) and TP/LP peptides (right). For each structural model, helix
8 is colored green, the terminal loops are colored gray, and the side
chain moieties of T553/L558 residues and their proline counterparts
are colored red. (B) Far-UV spectra of the WT peptide (40 μM)
in the absence (black) and presence (red) of 5 mM DPC. (C) Far-UV
spectra of the TP/LP peptide (40 μM) in the absence (black)
and presence (red) of 5 mM DPC. (D and E) Molecular dynamics simulations
for each peptide. Root-mean-square deviations (rmsd) of backbone atoms
(N, Cα, and C) within each simulated structure relative to the
initial modeled structure of helix 8 of M3R WT (D) and TP/LP (E) as
a function of simulation time are shown.We modeled the structures of WT and TP/LP peptides and conducted
molecular dynamics simulations in water solvent (Figure 3D,E). Interestingly, our MD analysis reveals that the WT peptide
reaches structural equilibrium with a root-mean-square deviation (rmsd)
of ∼7 Å (Figure 3D), implying that
it is extremely unstable in water because of its intrinsic structural
flexibility. This observation is consistent with our CD data showing
that the WT peptide adopts a random coil conformation in aqueous solution
and becomes α-helical only in the presence of an apolar membrane.
Likewise, the stability of the TP/LP peptide in water is comparable
to that of the WT peptide (Figure 3E).
Helix
8 Is Required for M3R Trafficking, Signaling, and Gβ5-RGS7
Interaction
Next, we introduced the TP/LP mutation into the
full-length M3R (M3RTP/LP) and tested its sensitivity to
Gβ5-RGS7 in the Ca2+ signaling assay (Figure 4). Ca2+ responses to CCh were nearly
undetectable in cells transfected with the M3RTP/LP mutant.
Because helix 8 is necessary for GPCR trafficking,[46−48] we compared
the subcellular localization of M3RTP/LP to that of WT
M3R. Radioligand binding studies (Figure 5A)
and immunological detection of the HA-tagged receptor (Figure 6) revealed that surface expression of M3RTP/LP was severely compromised.
Figure 4
CCh-stimulated Ca2+ signaling is
severely impaired by
the M3RTP/LP mutation. Concentration dependencies of the
maximal Ca2+ response of WT M3R (black) or M3RTP/LP (red) in the absence (dashed lines) or presence (solid lines) of
Gβ5-RGS7 stimulated by CCh using fura2, as described in Experimental Procedures. Each data point is the
average ± SD of three coverslips from two independent experiments
(n = 6). Curves were fit using the GraphPad Prism
5 sigmoidal dose–response equation with variable slope.
Figure 5
Muscarinic antagonists act as pharmacological
chaperones for the
M3RTP/LP mutant. (A) [3H]NMS binding to WT M3R
(black bars) and M3RTP/LP (red bars) was performed on live
cells as described in Experimental Procedures. Antagonists were added to cells for 18 h and washed away prior
to incubation with [3H]NMS. All antagonists were used at
the final medium concentration of 100 nM, except for pirenzepine,
which was used at a concentration of 200 μM. Bar graphs show
means ± SD (n = 2). (B) Representative Western
blots of cells treated with the indicated antagonists at a concentration
of 100 nM. The separate right panel shows cells treated with 200 μM
pirenzepine. WT M3R or M3RTP/LP was detected using the
anti-HA antibody; the arrow indicates the presumably glycosylated
M3R species. The position of the molecular weight standards is indicated
to the left. Shown in the bottom panel is a Western blot of the same
samples probed for actin as a loading control.
Figure 6
Atropine treatment greatly enhances M3RTP/LP surface
expression. (A) CHO-K1 cells were transfected with M3R or M3RTP/LP tagged with the HA epitope at its N-terminus. Forty-eight
hours post-transfection, cells were fixed, immunostained under nonpermeabilizing
conditions, and analyzed by fluorescence microscopy using a 60×
objective lens. Prior to fixation, cells were incubated with 100 nM
atropine for 18 h (right panels). Shown are representative images
from two independent transfection experiments. (B–D) Cells
were detached, labeled with the phycoerythrine-conjugated anti-HA
antibody under nonpermeabilizing conditions, and analyzed by flow
cytometry as described in Experimental Procedures. Representative histograms for cells transfected with WT M3R (B)
or M3RTP/LP (C), with or without atropine treatment. The X-axis shows the fluorescence intensity of phycoerythrine
and the Y-axis the number of cells. The dark gray
peak overlaid on each histogram shows staining of nontransfected CHO-K1
cells used as the negative control. The light gray histogram shows
HA-positive transfected cells. Vertical blue lines denote the gate
for HA-positive cells. (D) Percent of HA-positive cells in the total
counted events. Cells transfected with WT M3R are denoted with black
bars and those with the M3RTP/LP mutant with red bars [means
± SD (n = 2)]. (E) Median fluorescence intensity
(MFI) of HA-positive cells [means ± SD (n =
2)].
CCh-stimulated Ca2+ signaling is
severely impaired by
the M3RTP/LP mutation. Concentration dependencies of the
maximal Ca2+ response of WT M3R (black) or M3RTP/LP (red) in the absence (dashed lines) or presence (solid lines) of
Gβ5-RGS7 stimulated by CCh using fura2, as described in Experimental Procedures. Each data point is the
average ± SD of three coverslips from two independent experiments
(n = 6). Curves were fit using the GraphPad Prism
5 sigmoidal dose–response equation with variable slope.Muscarinic antagonists act as pharmacological
chaperones for the
M3RTP/LP mutant. (A) [3H]NMS binding to WT M3R
(black bars) and M3RTP/LP (red bars) was performed on live
cells as described in Experimental Procedures. Antagonists were added to cells for 18 h and washed away prior
to incubation with [3H]NMS. All antagonists were used at
the final medium concentration of 100 nM, except for pirenzepine,
which was used at a concentration of 200 μM. Bar graphs show
means ± SD (n = 2). (B) Representative Western
blots of cells treated with the indicated antagonists at a concentration
of 100 nM. The separate right panel shows cells treated with 200 μM
pirenzepine. WT M3R or M3RTP/LP was detected using the
anti-HA antibody; the arrow indicates the presumably glycosylated
M3R species. The position of the molecular weight standards is indicated
to the left. Shown in the bottom panel is a Western blot of the same
samples probed for actin as a loading control.Atropine treatment greatly enhances M3RTP/LP surface
expression. (A) CHO-K1 cells were transfected with M3R or M3RTP/LP tagged with the HA epitope at its N-terminus. Forty-eight
hours post-transfection, cells were fixed, immunostained under nonpermeabilizing
conditions, and analyzed by fluorescence microscopy using a 60×
objective lens. Prior to fixation, cells were incubated with 100 nM
atropine for 18 h (right panels). Shown are representative images
from two independent transfection experiments. (B–D) Cells
were detached, labeled with the phycoerythrine-conjugated anti-HA
antibody under nonpermeabilizing conditions, and analyzed by flow
cytometry as described in Experimental Procedures. Representative histograms for cells transfected with WT M3R (B)
or M3RTP/LP (C), with or without atropine treatment. The X-axis shows the fluorescence intensity of phycoerythrine
and the Y-axis the number of cells. The dark gray
peak overlaid on each histogram shows staining of nontransfected CHO-K1
cells used as the negative control. The light gray histogram shows
HA-positive transfected cells. Vertical blue lines denote the gate
for HA-positive cells. (D) Percent of HA-positive cells in the total
counted events. Cells transfected with WT M3R are denoted with black
bars and those with the M3RTP/LP mutant with red bars [means
± SD (n = 2)]. (E) Median fluorescence intensity
(MFI) of HA-positive cells [means ± SD (n =
2)].It is known that membrane-permeable
antagonists can act as pharmacological
chaperones, improving surface expression of helix 8 mutants of muscarinic
M1[49] and vasopressin V2[50] receptors. This effect involves stabilization of the mutant
receptor in the endoplasmic reticulum, allowing it to pass quality
control of the secretory pathway.[51] Here,
to facilitate trafficking of M3RTP/LP, we applied the pharmacological
chaperone approach pretreating cells with the membrane-permeable muscarinic
antagonist atropine. We found that atropine treatment greatly enhanced
[3H]NMS binding in cells expressing M3RTP/LP from <2 to ∼50% of WT (Figure 5). Similarly, quantification of cell surface expression of HA-M3R
using flow cytometry showed that pharmacological chaperone treatment
led to a dramatic increase in the level of M3RTP/LP trafficking
(Figure 6). It is worth mentioning that atropine
also increased the level of [3H]NMS binding in cells expressing
i3 loop mutant M3RΔ304–390 by approximately
2-fold (data not shown).We also tested if other structurally
diverse muscarinic antagonists
such as scopolamine, dicyclomine, and pirenzipine were capable of
acting as a pharmacological chaperone (Figure 5). We found that cell surface expression of M3RTP/LP,
as detected by [3H]NMS binding (Figure 5A), was enhanced by incubation with each antagonist utilized
in this study. It is worth mentioning that the pharmacological chaperone
effect of pirenzipine was observed only when it was applied above
20 μM. Western blot analysis showed that cells transfected with
M3RTP/LP did not display a high-molecular mass species
(∼120 kDa) present in cells expressing WT M3R (Figure 5B). Treatment with antagonists caused the emergence
of this ∼120 kDa band in M3RTP/LP-expressing cells.
This band had a fuzzy appearance, which is characteristic of glycosylated
proteins. It was shown earlier for other GPCRs that treatment with
pharmacological chaperones results in enhanced glycosylation and trafficking
of GPCR mutants.[50] Despite the remarkable
rescue of M3RTP/LP surface expression by atropine, signaling
of the mutant remained severely impaired, and it did not respond to
CCh (Figure 7) or six other muscarinic agonists
(data not shown).
Figure 7
Pharmacological chaperoning of M3RTP/LP does
not restore
CCh-stimulated Ca2+ signaling. Concentration dependency
curves of the maximal Ca2+ release response in atropine-pretreated
cells to CCh measured by Fluo-8 fluorescence using FLIPR Tetra in
the absence of extracellular Ca2+, as described in Experimental Procedures. Cells were transfected
with WT M3R (solid black), M3R and Gβ5-RGS7 (dashed black),
M3RTP/LP (solid red), or M3RTP/LP and Gβ5-RGS7
(dashed red). The maximal change in fluorescence intensity of four
replicate wells was averaged (means ± SD) and plotted for each
concentration of CCh. Curves were fit using the GraphPad Prism 5 sigmoidal
dose–response equation with variable slope.
Pharmacological chaperoning of M3RTP/LP does
not restore
CCh-stimulated Ca2+ signaling. Concentration dependency
curves of the maximal Ca2+ release response in atropine-pretreated
cells to CCh measured by Fluo-8 fluorescence using FLIPR Tetra in
the absence of extracellular Ca2+, as described in Experimental Procedures. Cells were transfected
with WT M3R (solid black), M3R and Gβ5-RGS7 (dashed black),
M3RTP/LP (solid red), or M3RTP/LP and Gβ5-RGS7
(dashed red). The maximal change in fluorescence intensity of four
replicate wells was averaged (means ± SD) and plotted for each
concentration of CCh. Curves were fit using the GraphPad Prism 5 sigmoidal
dose–response equation with variable slope.Earlier studies have demonstrated that the abnormally
high receptor
density in overexpression systems allows M3R to couple to other G
proteins, including Gs.[52] To test whether
M3RTP/LP could activate Gs in transfected CHO-K1 cells,
we measured cAMP after cells were treated with atropine to enhance
its membrane expression. Forskolin-stimulated cAMP accumulation was
similar in cells expressing WT or mutant M3R, regardless of the presence
of Gβ5-RGS7 (Figure 8A). For WT M3R,
CCh-elicited cAMP accumulation had an Emax that was 85% of the forskolin-stimulated response (Figure 8B). Gβ5-RGS7 had no effect on Emax or EC50, approximately 10 μM, which
were similar to those obtained in the Ca2+ imaging assay,
indicating that the cAMP response was M3R-specific. However, the Emax for M3RTP/LP reached only 10%
of that of the WT receptor (Figure 8B). Collectively,
our data show that atropine enhances membrane expression of M3RTP/LP, and this mutant is capable of binding ligand; however,
coupling to both Gq and Gs is nearly abolished.
Figure 8
Helix 8 mutant of M3R
cannot activate Gs. Cells were transfected
and treated with atropine as described in the legends of Figures 6 and 7. Forty-eight hours
post-transfection, cells were dissociated, seeded, and analyzed for
cAMP accumulation using the ULight competitive cAMP immunoassay kit
(PerkinElmer) as described in Experimental Procedures. Cells expressing WT M3R (black) or M3RTP/LP (red) in
the absence (solid) or presence (dashed) of Gβ5-RGS7 were stimulated
with increasing concentrations of forskolin (A) or CCh (B). Data are
presented as the percent response elicited by 10 μM forskolin-treated
cells as 100% control and buffer-treated cells as 0% control according
to the formula % response = 100[(negative control) – sample]/[(negative
control) – (positive control)]. Each point represents the mean
± SD of four replicate wells, and curves were fit using the sigmoidal
nonlinear regression equation with variable slope (GraphPad Prism
5.0).
Helix 8 mutant of M3R
cannot activate Gs. Cells were transfected
and treated with atropine as described in the legends of Figures 6 and 7. Forty-eight hours
post-transfection, cells were dissociated, seeded, and analyzed for
cAMP accumulation using the ULight competitive cAMP immunoassay kit
(PerkinElmer) as described in Experimental Procedures. Cells expressing WT M3R (black) or M3RTP/LP (red) in
the absence (solid) or presence (dashed) of Gβ5-RGS7 were stimulated
with increasing concentrations of forskolin (A) or CCh (B). Data are
presented as the percent response elicited by 10 μM forskolin-treated
cells as 100% control and buffer-treated cells as 0% control according
to the formula % response = 100[(negative control) – sample]/[(negative
control) – (positive control)]. Each point represents the mean
± SD of four replicate wells, and curves were fit using the sigmoidal
nonlinear regression equation with variable slope (GraphPad Prism
5.0).
Discussion
Understanding
how GPCRs interact with accessory proteins is an
important area of signal transduction, cell biology, and pharmacology.
In this paper, we extend our previous studies investigating the structural
basis of the interaction between the Gβ5-RGS7 complex and M3R.
Using a GST pull-down approach, we showed that recombinant fragments
of M3R could bind to the Gβ5-RGS7 complex.[14] Specifically, a central region of the i3 loop spanning
amino acids 304–390 bound the recombinant DEP domain of RGS7
with an affinity similar to that of the full-length i3 loop (residues
253–492). Here, we analyzed four i3 loop deletion mutations
in the context of the full-length receptor and found that two deletions
in the region of residues 304–345 rendered M3R-stimulated Ca2+ signaling nearly insensitive to Gβ5-RGS7 regulation
(Figure 1). Earlier work showed that the i3
loop of M3R interacts with several proteins, including Gq, Gβγ,
calmodulin, and SET, and contains a number of phosphorylation sites.[19,53−56] Our analyses of the region of residues 304–345 did not reveal
homology to other proteins or particular structural features, but
Gβγ docking and GRK phosphorylation have been mapped to
this region.[20] These results suggest that
the Gβ5-RGS7 complex may attenuate M3R-stimulated Ca2+ signaling by hindering Gβγ docking.In addition
to the i3 loop, our previous studies indicated that
the carboxyl terminus of the receptor (M3R CT) is required for interaction
with Gβ5-RGS7. We investigated the importance of two features
of M3R CT, the central polybasic stretch, 565-KKKRRK-570, and helix
8. The polybasic region was implicated in inactivate-state preassembly
of Gq heterotrimers.[43] Therefore, we hypothesized
that Gβ5-RGS7 could obstruct this mechanism by competing with
Gq for this binding site. However, our pull-down data suggest that
there may be a complex interaction at this region as Lys-to-Ala substitution
weakens DEP but not Gβ5 interaction (Figure 2). In contrast, we found that amino acid substitutions in
helix 8 abolished the interaction with both DEP and Gβ5 (Figure 2D,E). Helix 8 is a common structural motif present
in many GPCRs, which is involved in several processes, including membrane
trafficking and G protein recognition and activation.[57−60] Our circular dichroism spectroscopic experiments and molecular dynamics
simulations (Figure 3) support our hypothesis
that substitution of two helix 8 residues with Pro destabilizes its
α-helical fold. Given that Pro is known to disrupt α-helices,
because of its inability to participate in backbone hydrogen bonding,
this result may not be surprising. However, the destabilization of
helix 8 with the double Pro substitution became apparent only in a
phospholipid environment (Figure 3). The dependence
of helix 8 folding on the presence of membrane mimetics was previously
observed for peptides from cannabinoid and β2 adrenergic receptors[61−64] and thus appears to be a common motif among rhodopsin-like GPCRs.
Taken together, our results indicate that residues 548–567
of the carboxyl terminus of M3R form an α-helix and suggest
that its structural integrity is necessary for interaction with Gβ5-RGS7.In the course of this study, we found that membrane expression
of full-length M3RTP/LP was severely impaired (Figures 5 and 6). This observation
is consistent with previous work on helix 8 mutants of V2R and M1R.[49−51] To improve surface expression, we applied the pharmacological chaperone
approach by treating cells with atropine or other antagonists. Despite
the dramatic improvement of M3RTP/LP membrane expression
levels (Figures 5 and 6), its Ca2+ signaling remained impaired, with the Emax for CCh reaching only 10% of that of WT
in the millimolar range of CCh (Figure 7).
These functional studies of M3RTP/LP did not allow us to
probe Gβ5-RGS7 regulation without interfering with G protein
coupling. Thus, at the moment, our model in which helix 8 plays a
role in sensitizing M3R to Gβ5-RGS7 is based on the GST pull-down
studies (Figure 2).Helix 8 is known
to participate in conformational changes that
occur upon receptor activation.[29] Recently,
we reported that intrinsic properties of muscarinic agonists can determine
the sensitivity of M3R to Gβ5-RGS7 regulation.[13] This finding implied that some compounds might stabilize
a M3R conformation that is more conducive to Gβ5-RGS7 interaction.
Thus, we hypothesized that an agonist other than CCh may overcome
the structural instability introduced by the Pro substitutions. However,
none of the tested agonists were able to elicit a signal above the
CCh response (Figure 7). We also found that
the M3RTP/LP mutant was incapable of activating another
G protein, Gs (Figure 8). These results indicate
that the integrity of helix 8 is essential for G protein coupling.It is worth noting that in the course of our analyses we found
that Gβ5-RGS7 does not inhibit the activation of Gs by the overexpressed
WT M3R (Figure 8). This overexpression experiment,
although superficial, implies that Gβ5-RGS7 selectively inhibits
the Gq/PLC pathway. Consistent with our findings, previous biochemical
studies revealed that the complex had no effect on AC activity but
reduced PLC-β2 activity.[65] Thus,
we can speculate that regulation of M3R signaling by Gβ5-RGS7
involves two mechanisms: selective interaction of the complex with
M3R and competitive inhibition of PLC-β.In conclusion,
we have demonstrated that the 40 central amino acids
in the i3 loop of M3R are necessary for its regulation by the Gβ5-RGS7
complex and found that helix 8 likely plays a role in this interaction.
As is the case with other investigated GPCRs, the structural integrity
and conformational dynamics of M3R helix 8 are crucial for membrane
expression and G protein coupling.
Authors: Simone L Sandiford; Qiang Wang; Konstantin Levay; Peter Buchwald; Vladlen Z Slepak Journal: Biochemistry Date: 2010-06-22 Impact factor: 3.162
Authors: Amanda Barone Pritchard; Stanley M Kanai; Bryan Krock; Erica Schindewolf; Jennifer Oliver-Krasinski; Nahla Khalek; Najeah Okashah; Nevin A Lambert; Andre L P Tavares; Elaine Zackai; David E Clouthier Journal: Am J Med Genet A Date: 2020-03-05 Impact factor: 2.802